周期队列中高比例未成熟卵母细胞不影响ICSI后的胚胎发育或活产率
这项回顾性队列研究纳入2014年12月至2023年12月单中心学术附属生殖诊所的22117个IVF-ICSI周期,按成熟(MII)卵母细胞比例分组。极低MII比例(≤0.25)组囊胚形成数和PGT-A利用率显著降低,但倾向性评分匹配后每移植活产率与100%MII组无显著差异。
要点
- 极低MII比例(≤0.25)组囊胚形成数显著低于100%MII组,但匹配后活产率无显著差异。
- 低MII比例(≤0.5)组冷冻移植率呈降低趋势,新鲜移植率相当。
- 结果提示个体化促排卵方案优化成熟卵母细胞获取的重要性。
核心结论
- 高比例未成熟卵母细胞与较低囊胚形成率和PGT-A利用率相关,但平衡年龄、BMI、促性腺激素剂量和MII数等混杂因素后活产率仍相当。
- 极低MII比例周期导致胚胎移植数减少,构成数量上的限制,即使胚胎质量似乎未受影响。
研究设计与样本
- 回顾性队列研究,2014年12月至2023年12月单中心学术附属生殖诊所,纳入22117个IVF-ICSI周期。
- 按成熟(MII)卵母细胞比例分为三组:极低MII比例(≤0.25)、低MII比例(≤0.5)和100%MII卵母细胞。
- 采用两阶段倾向性评分匹配(PSM):第一阶段调整年龄、BMI、促性腺激素剂量和抗苗勒管激素水平;第二阶段调整年龄、BMI、促性腺激素剂量和MII数。
主要发现
- 极低MII比例(≤0.25)组囊胚形成数均值1.32(SD 2.77;95%CI 1.03-1.61) vs 100%MII组3.10(SD 3.22;95%CI 2.77-3.43),P<0.001。
- 极低MII比例(≤0.25)组PGT-A正常百分比均值34%(95%CI 30-38%) vs 100%MII组40%(95%CI 36-44%),P<0.001。
- PSM后,极低MII组与100%MII组每移植活产率在冷冻移植(41.6% vs 30%,P=0.68)和新鲜移植(46.1% vs 38%,P=0.69)中均无显著差异。
- 低MII比例(≤0.5)组冷冻移植率呈降低趋势(44% vs 53%,P=0.05),新鲜移植率相当(30% vs 26.6%,P=0.55)。
临床怎么用
- 作者认为结果强调个体化卵巢刺激方案以优化成熟卵母细胞(MII)获取并支持成功结局的重要性,即使在高比例未成熟卵母细胞的患者中。
局限性
- 本研究受回顾性性质和依赖电子病历的限制。
- PSM有效减少了混杂,但未直接测量固有卵母细胞质量标志物(如线粒体功能)。
- 各组MII比例分布不均匀可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does a high proportion of immature oocytes impact embryo development and live birth rates in IVF-ICSI cycles? SUMMARY ANSWER: While a high proportion of immature oocytes is associated with lower blastocyst formation and reduced preimplantation genetic testing for aneuploidy (PGT-A) utilization, live birth rates remain comparable when key confounders-such as age, BMI, gonadotropin dosage, and metaphase-II (MII) count-are balanced, but cycles with a very low MII proportion resulted in fewer embryo transfers, which is quantitatively limiting, even if embryo quality appears unaffected. WHAT IS KNOWN ALREADY: Previous studies have linked a lower proportion of mature oocytes (MII) to decreased fertilization rates, abnormal embryo development, and lower pregnancy and live birth rates. However, it remains unclear whether these outcomes are due to quantitative limitations (fewer mature oocytes available) or qualitative deficiencies (intrinsic oocyte quality issues). The impact of high proportions of immature oocytes on downstream IVF outcomes remains controversial. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study at a single academically affiliated fertility clinic between December 2014 and December 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: 22 117 patients undergoing IVF-ICSI cycles were categorized into three groups based on the proportion of mature (MII) oocytes: very low MII proportion (≤0.25), low MII proportion (≤0.5), and 100% MII oocytes. Propensity score matching (PSM) was applied in two phases: first, adjusting for age, BMI, gonadotropin dosage, and anti-Müllerian hormone levels; second, adjusting for age, BMI, gonadotropin dosage, and MII count. MAIN RESULTS AND THE ROLE OF CHANCE: Cycles with a very low MII proportion (≤0.25) had significantly lower blastocyst formation-mean 1.32 (SD 2.77; 95% CI: 1.03-1.61) versus 3.10 (SD 3.22; 95% CI: 2.77-3.43; P < 0.001)-and reduced PGT-A utilization-mean percent PGT-A normal 34% (95% CI: 30-38%) versus 40% (95% CI: 36-44%; P < 0.001). However, after PSM, live birth rates per an embryo transfer did not differ significantly between very low MII and perfect MII groups for both cryopreserved transfers (41.6% versus 30%, P = 0.68) and fresh embryo transfers (46.1% versus 38%, P = 0.69). The low MII proportion group (≤0.5) showed a trend toward lower cryopreserved transfer rates (44% versus 53%, P = 0.05), while fresh transfer rates remained comparable (30% versus 26.6%, P = 0.55). LIMITATIONS, REASONS FOR CAUTION: This study is limited by its retrospective nature and reliance on electronic medical records. While PSM effectively reduced confounding, inherent oocyte quality markers (e.g. mitochondrial function) were not directly measured. Additionally, the non-uniform distribution of MII proportions across groups may have influenced statistical power. WIDER IMPLICATIONS OF THE FINDINGS: These results underscore the importance of personalized ovarian stimulation protocols to optimize mature oocyte (MII) yield and support successful outcomes, even in patients with high proportions of immature oocytes. STUDY FUNDING/COMPETING INTEREST(S): The study was not funded. No competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Sripada V, Sakkas D, Vaughan D, et al. A high proportion of immature oocytes in a cycle cohort does not compromise embryo development or live birth rates after ICSI. Hum Reprod. 2025. PMID: 40912262. doi:10.1093/humrep/deaf167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。